Skip to main
RNAC

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics is expected to be a strong investment opportunity due to its unique technology and manufacturing platform for cell therapy, which can provide mRNA into cells for treating autoimmune diseases. The company's lead candidate, Descartes-08, has shown promising results in early clinical studies with its favorable safety profile, sustainability, and redosing potential setting it apart from other treatment options. In addition, Cartesian's strategic partnerships and collaborations further validate the potential of its platform. Overall, Cartesian Therapeutics has the potential to achieve commercial success and become a preferred treatment option in the autoimmune disease market, making it a strong investment opportunity.

Bears say

Cartesian Therapeutics is expanding their clinical programs through a partnership with WestGene, giving them access to a targeted LNP platform and allowing them to advance their own next-generation anti-BCMA CAR and TCE constructs. This collaboration provides a capital-efficient pathway for Cartesian to expand beyond their current ex vivo strategies and leverage their previous clinical experience. While the financial terms were not disclosed, the partnership is not expected to significantly impact Cartesian's cash runway guidance.

RNAC has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 5 analysts, RNAC has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.